Company Overview
Prelude Therapeutics Incorporated operates as a clinical-stage precision oncology company dedicated to the discovery and development of novel precision cancer medicines designed specifically for underserved patient populations. Within the broader Healthcare sector, the firm functions within the specialized Biotechnology industry, where its primary focus is on creating targeted therapies for complex conditions such as myeloproliferative neoplasms and myelofibrosis. The company currently maintains a market capitalization of $204.94M, reports annual revenue of $12.14M, and employs a workforce of 79 individuals. These valuation and revenue figures indicate that Prelude Therapeutics is a small-cap entity operating with limited resources, a status typical for clinical-stage biotechnology firms that are still navigating the high-cost phases of drug development without yet generating significant commercial profits.
Financial Health
The company reported a total revenue of $12.14M over the trailing twelve months, while the net income stood at -$99,498,000 and the EBITDA was -$101,555,000. The substantial gap between the positive revenue figure and the deeply negative net income reveals a cost structure dominated by research and development expenditures and operational burn rates that are common in the early stages of biotechnology innovation. Free cash flow for the period was -$23,872,250, indicating that the company is currently consuming cash reserves to fund its operations rather than generating surplus liquidity from its core business activities. This negative cash flow situation implies a reliance on external financing or existing cash holdings to sustain day-to-day operations and research programs. Regarding profitability metrics, the company achieved a Gross Margin of 100.0%, reflecting the high gross profit margins often seen in biotech prior to significant cost of goods sold scaling, though the Operating Margin is -284.5% and the Profit Margin is 0.0%, signaling that overhead costs and R&D expenses are far outpacing gross revenue generation. The firm holds $103.21M in cash against $17.79M in debt, resulting in a Debt to Equity ratio of 25.92, which suggests a balance sheet that is heavily weighted toward equity financing with minimal leverage. Despite the low debt load, the Current Ratio of 1.99 indicates that the company possesses sufficient current assets to cover its short-term liabilities nearly twice over, providing a buffer for immediate financial obligations. Return on Equity is recorded at -99.5% and Return on Assets is -40.7%, metrics that reflect the significant dilution of shareholder value and asset efficiency during the pre-revenue or low-revenue growth phase typical of clinical-stage development.
Valuation Assessment
Prelude Therapeutics has a Trailing P/E ratio of N/A due to its lack of positive net income, while the Forward P/E is listed at -2.85, a metric that implies the market prices in future earnings recovery or continued losses depending on the direction of the numerator. The Price to Book ratio stands at 3.92, indicating that the market values the company at nearly four times its book value, a significant premium that reflects the potential intrinsic value of its intellectual property and pipeline assets rather than its current tangible net worth. Alternative valuation metrics such as the Price to Sales ratio of 16.88 and the EV/EBITDA of -1.81 suggest that the company is being valued primarily on its revenue generation potential and sales pipeline rather than traditional profitability standards. The stock has traded between a 52-Week High of $4.22 and a 52-Week Low of $0.61, meaning the current price sits at a level that reflects high volatility within this compressed trading range. The Beta value of 0.87 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it moves less dramatically than the overall market index during periods of fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at 41.0%, demonstrating a robust expansion in top-line sales, whereas Earnings Growth is listed as N/A due to the company's reported net losses. Because earnings are not growing in the traditional sense of profit expansion but rather from a loss position, the 41.0% revenue growth is the primary driver of company expansion, implying that sales volume is increasing faster than the rate of cost escalation. As a non-dividend payer, the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%, which signifies that all generated cash is reinvested into growth initiatives such as clinical trials and drug development rather than distributed to shareholders. The overall growth and income profile characterizes Prelude Therapeutics as a high-risk, high-reward asset where value is derived entirely from future commercialization potential rather than current income generation or dividend stability.